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Vesicular stomatitis virus (VSV) is a rhabdovirus which causes acute encephalitis in mice after intranasal infection. Because type I
interferon (IFN) has been shown to be a potent inhibitor of VSV, we investigated the role of type I IFN in viral replication in neurons in
culture. Pre-treatment of NB41A3 neuroblastoma cells or primary neuron cultures with IFN-h or IFN-a strongly inhibits virus replication,
with 1000-fold inhibition of infectious virus release occurring at 7 h post-infection, and maximum inhibition of 14,000-fold occurring at 14 h.
Type I IFN inhibited both viral protein and RNA synthesis, but not enough to account for the inhibition of infectious virus yield. The
influenza virus protein NS1 binds dsRNA and antagonizes induction of PKR activity, an IFN-inducible antiviral protein which
phosphorylates and inactivates the elongation factor eIF-2a, resulting in cessation of translation. In NS1-expressing neuroblastoma cells,
VSV replication was inhibited by IFN-h as well as in control NB41A3 cells, and eIF-2a phosphorylation was blocked, suggesting that PKR
activity was not involved in inhibition of viral protein synthesis. Similarly, inhibition of VSV by IFN-h was not affected by addition of
inhibitors of nitric oxide synthase, indicating that IFN-h activity is not mediated by nitric oxide or superoxide. This contrasts with the
essential role of NOS-1 in inhibition of VSV replication when neurons are treated with IFN-g. Analysis of cell culture supernatants revealed
suppression of release of VSV particles from both NB41A3 cells and primary neurons treated with IFN. The inhibition of virion release
closely matched the overall suppression of infectious VSV particle release, suggesting that type I IFN plays a role in inhibition of VSV
assembly.
D 2005 Elsevier Inc. All rights reserved.
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VSV is a rhabdovirus that upon intranasal (i.n.)
inoculation of mice causes severe and rapid encephalitis
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promotes rapid access of VSV to the central nervous
system (CNS), where VSV replicates to high titers. In
contrast, other routes of administration generally lead to
little or no CNS or peripheral viral replication and no
apparent clinical disease. The reasons behind the ability of
VSV to replicate in the CNS are not known, but may
involve increased neurotropism compared to non-neural
tissues as well as differing immune responses in the central
nervous system compared to peripheral sites. Indeed,
evidence for the latter possibility exists in that mice
deficient in the type I IFN receptor (IFNAR1) were highly
susceptible to i.v. VSV infection, while immunocompetent05) 215–225
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mice succumbed to VSV infection very rapidly and had
high viral titers in all organs tested (both neural and non-
neural), in contrast to wild-type mice which cleared VSV
rapidly from peripheral sites. Similarly, mice deficient in
STAT1 also succumbed rapidly to i.v. administration with
VSV, with high viral titers detectable in the liver (Durbin et
al., 1996). Mice deficient in the dsRNA-dependent protein
kinase (PKR), an IFN-inducible antiviral protein, suc-
cumbed very rapidly to i.n. VSV infection (Stojdl et al.,
2000). In this case, mice died because of overwhelming
respiratory tract pathology, and not CNS disease as
normally observed in i.n.-inoculated mice. In each case,
VSV replication was high in the brains of both immuno-
competent and immunodeficient mice. Such results suggest
that type I IFN plays a critical role in control of VSV
replication in peripheral organs of mice, while having little
or no role in VSV replication in the CNS.
Several possibilities exist for the discrepancy between
VSV replication in the CNS and periphery when it comes to
type I IFN. One possibility is that type I IFN cannot inhibit
VSV replication in murine neurons. To investigate this
possibility, the ability of type I IFN to inhibit VSV
replication in cultured and primary neurons was inves-
tigated. It was shown that both primary olfactory and
cultured neurons were highly sensitive to the inhibitory
effect of IFN when assayed at early times post-infection.
Unlike IFN-g-mediated inhibition of VSV in neurons
(Chesler et al., 2003; Komatsu et al., 1996), the inhibition
of VSV replication was not due to nitric oxide, nor to PKR.Fig. 1. Type I IFN strongly inhibits VSV replication in neuroblastoma cells. NB41A
24 h, and then infected with VSV at an moi = 0.01. At 7 h p.i., cell supernatants w
plaque assay to determine viral titer. (C) Alternatively, NB41A3 cells were incubat
moi = 0.1. (D) Inhibition of VSV replication was monitored by standard plaque as
type I interferon for 18 h and then infected with VSV at moi = 0.1 for various tim
shown in filled circles. Untreated MDBK cells are shown in filled squares while IF
IFN was monitored by standard plaque assay.Interestingly, IFN exerted its effect at multiple stages of
replication, as viral RNA and protein synthesis as well as
viral assembly was inhibited in neurons.Results
Type I IFN strongly inhibits VSV replication in neurons
NB41A3 neuroblastoma cells were originally derived
from a murine neuron neoplastic tumor, and possess many
properties of sympathetic neurons, such as synthesis and
storage of catecholamines (Breakfield et al., 1975) and
development of neurotubules and neurofilaments (Schubert
et al., 1969). NB41A3 cells were also shown to be very
similar to primary olfactory neurons in their response to
IFN-g-treatment, as NOS-1 levels were increased post-
treatment and nitric oxide was shown to be wholly
responsible for the observed inhibition of VSV replication
by IFN-g in both cell types (Chesler et al., 2003). In
addition to primary neuron cultures, NB41A3 cells were
used as a cell culture model of neurons in the present
study.
NB41A3 cells were treated with varying amounts of
IFN-h for 24 h and then infected with VSV at a multiplicity
of infection (moi) of 0.01. Infection was allowed to proceed
for 7–8 h and viral titers in cell supernatants were assayed
by plaque formation on CHO cell monolayers. As shown in
Fig. 1A, IFN-h strongly inhibited VSV replication even at
low doses of IFN (b1 unit/ml), as did IFN-a (Fig. 1B).3 cells were pretreated with varying amounts of IFN-h (A) or IFN-a (B) for
ere harvested and inhibition of VSV replication was monitored by standard
ed with 100 units/ml IFN-h for various times and then infected with VSVat
say. NB41A3 or MDBK cells were also treated with 400 units/ml universal
es, IFN-treated NB41A3 cells are shown in open circles; untreated cells are
N-treated cells are shown in open squares. Inhibition of VSV replication by
Fig. 2. Type I IFN strongly inhibits VSV replication in primary olfactory
neurons. Primary olfactory neurons were isolated from C57BL/6 or
BALB/c mice and cultured. Cells were either mock- or pre-treated with
IFN-h (100 units/ml) for 18 h, and then infected with VSV at moi = 0.1.
Cell supernatants were harvested at 7 h pi and inhibition of VSV
replication was monitored by standard plaque assay.
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moi = 0.1 and 1.0 (data not shown), although low levels of
virus was detected at 7 h pi at higher moi. To determine the
kinetics of the antiviral effect, NB41A3 cells were treated
with 100 units/ml IFN-h for various times, and then
infected with VSV to determine antiviral effect as measured
by reduced plaque formation (Fig. 1C). Almost 10-fold
inhibition of VSV replication could be observed with as
little as 2 h pre-treatment with IFN-h, with increasing
inhibition over time. Maximal inhibition of VSV replication
was observed after 8 h pretreatment with IFN-h. A modest
amount of inhibition could be seen with 1 h pre-treatment
of cells with IFN-h. Significant inhibition of VSV
replication by type I IFN could be observed up to 32 h
post-infection (pi) (Fig. 1D). Inhibition of VSV replication
by IFN peaked at 14 h pi at almost 14,000-fold. Viral titer
production in untreated cells reached a plateau at around
this time, likely due to exhaustion of viable host cells in
which replication could take place. Surprisingly, viral titer
production in IFN-treated cells continued to increase until
26 h pi, with peak titers still being approximately 5- to 10-
fold less than that observed at comparable times in
untreated cells. The first signs of cytopathic effect (CPE)
in untreated NB41A3 cells were observed at 10 h pi, and
most cells were apoptotic and detached from the plate at 14
h pi. In contrast, CPE was not observed until approximately
22 h pi in IFN-treated cells. Despite lower viral titers, IFN-
treated NB41A3 monolayers were non-viable by 30 h pi,
indicating that either VSV replication was merely delayed
in IFN-treated NB41A3 cells (data not shown) or that the
cytostatic effect of IFN lead to apoptosis in infected, treated
neuronal cells.
To determine whether the ability of VSV to replicate in
and kill IFN-treated cells was restricted to neuronal cells,
Madin–Darby bovine kidney (MDBK) cells were pre-
treated with media or type I IFN (500 units/ml) and
challenged with VSV at 18 h post-treatment. The ability of
type I IFN to inhibit VSV replication in MDBK cells has
been demonstrated (Alexenko et al., 1999); MDBK cells
have also been used in bioassays to detect the presence of
type I IFN using VSV as challenge virus (Chehadeh et al.,
2000; Eichmann et al., 1990; Sperber et al., 1992).
Because they are of bovine origin, MDBK cells do not
respond to murine IFN (Chehadeh et al., 2000), universal
type I IFN (R&D Systems) was used in MDBK cell and
corresponding NB41A3 cell experiments shown in Fig.
1D. Untreated MDBK cells permitted VSV replication to
high titers (Fig. 1D), with CPE and cell death observed at
14 h (data not shown). IFN-treatment of MDBK cells
resulted in strong inhibition of VSV replication, however,
by 30 h, pi viral titers increased. CPE was observed at
40 h, and cell death was complete by 48 h. In contrast,
uninfected cells remained alive at this time point (data not
shown). The results indicate that that ability of VSV to
overcome IFN-mediated antiviral effects is not restricted to
neuronal cells.Type I interferon inhibits VSV replication in primary
olfactory neurons
Both BALB/c and C57BL/6 mice are susceptible to VSV-
induced encephalitis upon intranasal infection. Primary
olfactory neurons were isolated from neonatal BALB/c
and C57BL/6 mice, and treated with medium or IFN-h (100
u/ml) for 18 h before challenge with VSV (moi = 0.1). As
shown in Fig. 2, pre-treatment of primary olfactory neurons
with IFN-h profoundly inhibited VSV replication. Indeed,
the reduction of VSV titers in primary neurons from
C57BL/6 mice (675-fold) was comparable to that observed
in neuroblastoma cultures (~1000-fold). The reduction of
VSV titers in primary neurons from BALB/c mice was
similar (~3000-fold). These results indicate that primary
neuron cultures are responsive to type I IFN. Of note, VSV
showed increased replicative capacity in primary neurons
from BALB/c mice compared to that observed in C57BL/
6-derived neurons or neuroblastoma cells (compare Figs. 1
and 2), with supernatants from VSV-infected BALB/c
neurons containing almost 107 pfu/ml VSV at 7 h pi, while
supernatants from other infections averaged approximately
105 pfu/ml. Similarly, viral replication was increased in
IFN-treated BALB/c primary neurons, although the overall
inhibition was approximately 10-fold greater than that
observed in neuroblastoma cells or C57BL/6 primary
neurons.
VSV protein levels are decreased in IFN-btreated neurons
To determine the mechanism of inhibition of VSV
replication in neurons by IFN-h, Western blotting was
utilized to quantify the level of viral protein accumulation
in mock- or IFN-h-treated cells. Pre-treatment of NB41A3
cells with IFN-h led to a decrease in levels of VSV G, N/P,
and M proteins in VSV-infected cells (Fig. 3A). The level of
inhibition varied, but typically was in the range of 3- to 20-
fold, depending on the gene product and the time post-
Table 1
Quantification of inhibition of VSV replication by IFN-h in various
neuronal cells
Cell type Hours pi Fold inhibitiona
(+/ SD)
NB41A3 7–8 973 F 330b
NB41A3 10 3972 F 275
NB41A3 14 13,864 F 684
NB41A3 18 10,003 F 753
NB41A3 22 846 F 61
NB41A3 26 55 F 18
NB41A3 30 53 F 4.5
Primary neuron:
C57Bl/6 7 755 F 345c
Balb/c 7 3078 F 391c
a Data represent mean F SD for n = 3 samples unless otherwise indicated.
b n = 8.
c n = 2.
Fig. 3. VSV protein and RNA levels are reduced after IFN-h treatment of
neurons. NB41A3 (A) and primary olfactory neurons from BALB/c mice (B)
were mock- or pre-treated with IFN-h (100 units/ml) for 18 h, infected with
VSVat moi = 0.1 or 1, and cell lysates were harvested at indicated times pi.
Lysates were subjected to Western blotting to detect the presence of viral
proteins. The mouse housekeeping gene GAPDH served as a loading control.
For detection of viral RNA in mock- and IFN-treated NB41A3 cells, total
RNA harvested at various times post-infection was subjected to Northern
blotting and viral mRNA (C) and full-length genomic RNA (D) were
detected. The left lane in (D) (labeled bvQ) represents RNA isolated from
purified VSV particles. PCR-DIG-labeled probes (Roche) for the viral RNAs
encoding VSV G, M, N, L, and P, along with the mouse housekeeping gene
GAPDH, were hybridized to RNA blots and detected by chemiluminescence.
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levels in IFN-treated cells (Table 2). The observed decrease in
VSV protein accumulation in IFN-treated NB41A3 cells at 7
h pi did not account for the observed inhibition of infectious
virus release by these cells at this time (~1000-fold; Table 1).
In primary olfactory neurons, VSV protein levels were
also reduced by IFN-h treatment (Fig. 3B). As in NB41A3
cells, protein levels were reduced to a lesser extent than
release of infectious virus (compare Tables 1 and 2). Cell
lysates from BALB/c primary neurons showed an approxi-
mately 30- (VSV M and VSV N/P) to 80-fold (VSV G)
reduction in protein expression at 7 h pi (Table 2), while
infectious virus production was inhibited 3000-fold (Table 1).
Viral RNA levels are decreased in IFN-b-treated neurons
Total RNA from VSV-infected NB41A3 cells either pre-
treated with IFN-h or mock-treated with media wassubjected to Northern blotting to detect the presence of
mRNAs for VSV genes M, N, L, P, and G using DIG-
labeled DNA probes. Viral RNA accumulation was reduced
in IFN-h-treated cells, with reduction being the greatest at
7 h pi (Fig. 3C). Little inhibition of RNA accumulation was
observed at 2 h pi. The level of reduction at 4 and 7 h pi
ranged from 3- to 12-fold depending on time pi and gene
(Table 2). Accumulation of full-length viral genomic RNA
was also inhibited to a similar extent as viral mRNAs (Fig.
3D). As for protein levels, the moi had little effect on
inhibition by IFN (Table 2). Also like protein levels, the
level of inhibition of RNA accumulation by IFN did not
account for the drop in infectious virus production (Table 1).
PKR is not involved in inhibition of VSV by IFN-b
The dsRNA-dependent protein kinase (PKR) has been
shown to have potent antiviral effects in various systems,
including playing a role in inhibition of VSV replication in
vitro and in vivo (Stojdl et al., 2000). NS1 binds to dsRNA,
a stimulus of PKR activity (Li et al., 2004). The influenza
NS1 gene has been shown to have an inhibitory effect on
IFN action (Bergmann et al., 2000). One of the effects of the
NS1 protein is inhibition of PKR in infections by both
influenza A and Newcastle disease virus (NDV). To analyze
the role of PKR in inhibition of VSV by IFN-h, a plasmid
encoding the influenza NS1 protein was stably transfected
into NB41A3 cells (Chesler et al., 2003). NS1 has been
shown to inhibit IRF-3 nuclear translocation caused by
NDV infection (Talon et al., 2000). To verify NS1
expression, the ability of NDV to activate IRF-3, causing
translocation to the nucleus, was analyzed.
Immunofluorescence studies on IRF-3 subcellular loca-
lization indicated that NDV infection of NB41A3 cells
induced nuclear translocation of IRF-3 as early has 1 h pi,
with increasing nuclear translocation of IRF-3 over time (up
to 4 h tested) (Fig. 4A). In contrast, NB41A3 cells
expressing NS1 (NB41A3.NS1) showed little or no nuclear
Table 2
Quantification of inhibition of VSV RNA, intracellular protein synthesis, and incorporation of proteins into particles by IFN-h at 7 h pi
Cell type RNA levelsa Protein levelsb Incorporation into particlesc
G N M/Pd G N/Pe M G M
NB41A3 (moi = 0.1) 3.5, 9.0 4.7, 7.2 3.2, 11.8 11.7 F 4.4 5.0 F 1.6 16.3 F 13.1 325 200
NB41A3 (moi = 1.0) 4.3 3.8 7.2 8.8 2.4 4.4 240 125
18 Neuronsf nd nd nd 34, 70.9 33.6, 29.6 17, 47.5 N50 N50
Results are expressed as the fold-inhibition in IFN-treated cells compared to mock-treated cells at 7 h pi.
a Northern blot analysis of VSV RNA.
b Data are average F SD, n = 3 determinations, for moi = 0.1.
c No VSV particles were detected in primary cultures at 7 h pi.
d VSV M and P mRNAs are of similar size.
e VSV N and P proteins migrate at the same rate in SDS-PAGE.
f Primary BALB/c neuron cultures.
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functional NS1 is present in these cells (Fig. 4B).
Western blotting to detect the presence of phosphorylated
eIF-2a in NB41A3 and NB41A3.NS1 cells was performed
to assess the kinase activity of PKR. Cells were pretreated
with type I IFN and then infected with VSV for various
times. VSV infection led to modest increases in eIF-2aFig. 4. PKR is not involved in the inhibition of viral protein synthesis by IFN-h. N
the ability to block the antiviral effect of IFN-h via NS1-mediated inhibition of PK
nuclear translocation was monitored by immunofluorescence using anti-IRF-3 anti
B). NB41A3 cells (A) and NB41A3.NS1 cells (B) were infected with NDV for 1
nuclei (left panels in A and B). NB41A3 and NB41A3.NS1 cells were pre-treated
moi = 0.01. The ability of IFN to inhibit VSV replication in these cells was monphosphorylation at 4 and 7 h post-infection, with 1.9- to 4.4-
fold increases in phosphorylated eIF-2a observed in IFN-
treated, VSV-infected cells (Table 3). In contrast,
NB41A3.NS1 cells showed little or no increase in eIF-2a
phosphorylation in either untreated or IFN-treated cultures.
Unphosphorylated eIF-2a levels were fairly constant in all
samples. The results indicate that NS1 expressed inB41A3 cells expressing the influenza A virus NS1 protein were analyzed for
R. To determine if functional NS1 was expressed in NB41A3 cells, IRF-3
body (Zymed) after NDV infection for various times (right panels in A and
, 2, and 4 h. Nuclear localization of IRF-3 was compared to DAPI stained
with IFN-h (100 units/ml) for 18 h and subsequently infected with VSV at
itored by standard plaque assay (C).
Fig. 5. Nitric oxide is not involved in the inhibition of VSV replication by
IFN-h. NB41A3 cells were treated with IFN-g (25 ng/ml), IFN-h (100
units/ml) or medium alone in the presence or absence of the non-isotype-
specific NOS inhibitor l-NAME (500 AM) for 72 h (IFN-g) or 24 h (IFN-
h), followed by infection with VSV at moi = 0.01. Cell supernatants were
harvested at 8 h pi and assayed for infectious virus by standard plaque
assay.
Table 3
Quantification of eIF-2a phosphorylation in NB41A3 and NS1-expressing NB41A3 cellsa
Cell type NB41A3  IFNb NB41A3 + IFNc NB41A3.NS1  IFN NB41A3.NS1 + IFN
h pi 4 h 7 h 4 h 7 h 4 h 7 h 4 h 7 h
eIF-2a 0.76, 1.3d 0.14, 1.5 0.67, 0.78 0.91, 0.47 0.73, 0.46 0.09, 0.22 0.75, 0.87 0.90, 0.44
eIF-2a-P 1.9, 0.62 3.1, 0.98 2.1, 4.4 1.9, 4.2 1.5, 0.61 1.6, 0.43 1.1, 0.30 1.2, 0.45
Results are shown as the normalized expression of each protein compared to uninfected cells.
a Data derived from Western blots of cell lysates.
b Data represent fold change in expression compared to mock-infected cultures.
c Data represent fold change in expression compared to IFN-treated, mock-infected cultures.
d Data are presented as results from two different experiments
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rylation that is observed following VSV infection, with the
largest decrease occurring in IFN-treated cells (Table 3).
This observation is consistent with the published findings
that NS1 blocks host cell suppression of translation during
viral infection.
NB41A3.NS1 cells were treated with IFN-h for 24 h and
then challenged with VSV at a moi = 1. In control cells,
IFN-treatment resulted in strong inhibition of VSV repli-
cation as determined by plaque assay (Fig. 4C). Similarly,
IFN-treatment of NS1-expressing NB41A3 cells resulted in
strong inhibition of VSV replication. These results suggest
that PKR does not play a role in IFN-mediated inhibition of
VSV replication.
Nitric oxide is not involved in inhibition of VSV by IFN-b
IFN-g inhibits VSV replication in NB41A3 cells and
primary neurons, and this inhibition is mediated by nitric
oxide (Chesler et al., 2003; Komatsu et al., 1996). To
determine whether nitric oxide plays a role in IFN-h
inhibition of VSV, NB41A3 cells were treated with IFN-h
in the presence or absence of the NOS inhibitor l-NAME,
followed by infection with VSV. Viral replication was
analyzed by standard plaque assay of cell supernatants
harvested 7–8 h pi. As a control, NB41A3 cells were treated
with IFN-g for 72 h in the presence or absence of l-NAME,
as described previously (Chesler et al., 2003). IFN-g
treatment resulted in inhibition of VSV replication, and this
inhibition could be reversed by l-NAME, indicating nitric
oxide mediates IFN-g inhibition of VSV replication (Fig. 5).
In contrast, l-NAME had no effect on the inhibition of VSV
replication by IFN-h, indicating that nitric oxide did not
play a role in IFN-h inhibition of VSV in neurons (Fig. 5).
IFN-b inhibits assembly of infectious VSV particles
VSV replication is inhibited almost 1000-fold in
NB41A3 cells pretreated with IFN-h and infected with
VSV for 7 h (Table 1). However, viral RNA and protein
synthesis are inhibited to a much lesser extent. Because of
the accumulation of viral RNA and protein in NB41A3
cells, a potential defect in viral assembly was investigated
by quantifying viral particle release from infected cells. Todetermine the level of virus particle release from infected
cells, culture supernatants were subjected to ultracentrifu-
gation through 15% sucrose to pellet VSV particles.
Western blots were performed to quantify the level of
VSV proteins in the pellets. Analysis of cell supernatants
taken at 7 h pi revealed that there was a substantial reduction
of viral particles in IFN-h-treated NB41A3 supernatants
compared to mock-treated supernatants (Fig. 6). Quantifi-
cation of the results showed that VSV G protein in IFN-h-
treated cell supernatants was reduced approximately 200-
fold, while VSV M protein was reduced 330-fold at moi =
0.1 and slightly less at moi = 1 (Table 2), compared to
untreated infected control cells. These results are compara-
ble with the observed inhibition of infectious virus yield by
IFN (1000-fold at moi = 0.1, 500-fold at moi = 1),
suggesting that the majority of inhibition of VSV replication
in NB41A3 cells by IFN-h occurs at the assembly stage of
infection. The consistent ratio of M and G in the virions also
indicates that particles are not bbaldQ. Similar results were
observed in pellets of cell supernatants from primary neuron
cultures taken at 7 h pi (data not shown). However, because
of the relatively small number of cells in primary neuron
cultures, no infectious virus was detected in IFN-h-treated
neuron supernatants at 7 h pi. This corresponded to at least
50-fold inhibition of VSV particle release, based on serial
Fig. 6. VSV particle release into cell supernatant is inhibited by IFN-h.
NB41A3 cells were mock- or pre-treated with IFN-h (100 units/ml) for 18 h
and infected with VSV at moi = 0.1 (A) or moi = 1 (B). At 7 h p.i., cell
supernatants were harvested and subjected to ultracentrifugation through
15% sucrose. Pellets were subjected to Western blotting to detect the
presence of VSV proteins.
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supernatants (Table 2).Discussion
Intranasal inoculation of VSV into mice results in severe
encephalitis with high morbidity and mortality. The ability
of VSV to replicate in the CNS of immunocompetent mice
is in sharp contrast to that observed in the periphery. Type I
IFN has been shown to play a major role in the control of
VSV replication in non-neural tissue (Muller et al., 1994). In
this study, we investigated the role of type I IFN in VSV
infection of neurons. Pretreatment of murine neurons with
type I IFN severely restricted VSV replication early after
infection (Table 1, Fig. 1), and that this restriction was
caused by inhibition of viral RNA and protein synthesis
(Table 2, Figs. 2 and 3) as well as inhibition of viral
assembly and release (Fig 6). The mechanism(s) of
inhibition were shown to be distinct from that elicited by
IFN-g, which inhibits VSV replication in neurons through
the activity of NOS-1 (Chesler et al., 2003) (Figs. 4 and 5).
Of note, viral replication occurred to some degree in
IFN-treated cells, as viral protein and RNA accumulation
could be readily detected, even though infectious virus
release was very low. Following IFN pre-treatment of
neuronal cells (without IFN after adsorption of the virus
or during later incubation times), virus replication was most
compromised early after infection (8–14 h pi), after which
time VSV replication continued, eventually leading to death
of all cells and relatively high viral titers in culture
supernatants. Interestingly, late after infection all IFN-
treated cells were killed by VSV even when the moi was
as low as 0.01. This observation held true in non-neuronal
MDBK cells as well (Fig. 1D).
Generally, infection of cells by RNA viruses leads to
rapid induction of type I IFN production via cellular
recognition of viral dsRNA, protecting neighboring cells
from secondary infection; however this obviously does notoccur with VSV infection of neuronal cells. VSV infection
suppresses IFN production after infection of various cell
types (Marcus and Sekellick, 1978), blocking nuclear export
of host mRNA and host protein synthesis (Ahmed et al.,
2003), and does not induce IFN production from NB41A3
cells or primary neuron cultures (Trottier et al., in
preparation). These attributes of VSV infection of cells
likely result in the virus’ ability to replicate in and kill IFN-
treated cells, even at low moi. One hypothesis is that the
VSV M protein accumulates in IFN-treated cells, ultimately
leading to nuclear blockade of mRNA export (Enninga et
al., 2002; Petersen et al., 2000), and reversal of the IFN
antiviral effect. Experiments are currently underway to
investigate this hypothesis.
After intranasal inoculation of mice with VSV, most viral
replication occurs in the brain, while viral replication in the
periphery is limited (Kelley et al., 1972; Rosenthal and
Zinkernagel, 1980). In mice deficient in the type I IFN
receptor (IFNAR1/) or the signaling molecule, STAT-1,
VSV innoculation via the i.v. route leads to rapid and
overwhelming systemic infection and death. Wild-type mice
injected with VSV suffer no apparent clinical disease,
illuminating the critical importance of type I IFN in control
of VSV in mice (Muller et al., 1994). Mice deficient in PKR
also rapidly succumb to disease when infected by the
intranasal route, but by severe respiratory tract pathology, as
opposed to the CNS pathology normally observed with i.n.
infected immunocompetent mice (Stojdl et al., 2000); PKR
involvement in this phenomenon is mouse strain-dependent
(Durbin et al., 2002). The mechanisms by which IFN
controls VSV replication in the brains of immunocompetent
mice are not fully understood, however, PKR appears
unlikely to play a role in neurons, despite its importance
in the periphery (Stojdl et al., 2000).
Studies over the years in cell culture systems have
revealed that while many cell types display IFN sensitivity
with regard to inhibition of VSV replication, the mecha-
nisms by which these cells exert antiviral effects vary. For
example, in early studies in Vero cells and other human cell
lines, IFN treatment resulted in inhibition of primary
transcription of VSV genes (Belkowski and Sen, 1987;
Marcus and Sekellick, 1978; Thacore, 1978; Zhang and
Samuel, 1987). Alternatively, in simian cell cultures, IFN
treatment did not alter primary transcription and instead
inhibited VSV protein synthesis (Thacore, 1978). Similarly,
protein synthesis inhibition was determined to be the
mechanism behind IFN-mediated VSV inhibition in mouse
L929 cells and human amnion U cells, as primary tran-
scription was unaffected in the presence of IFN (Hoshino et
al., 1987; Masters and Samuel, 1983). It was later
determined that inhibition of VSV protein synthesis in
amnion U cells occurred via phosphorylation of eIF-2a
(Samuel and Knutson, 1983).
In each of these studies, either protein synthesis or RNA
replication was inhibited by IFN, and thus the IFN-
stimulated pathways that involve PKR or oligoadenylate
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interferon action. Indeed, microinjection of 2V–5V oligoade-
nylate into mouse L cells inhibited VSV replication in the
absence of IFN treatment (Higashi and Sokawa, 1982;
Panet, 1983). Also, IFN-mediated inhibition of VSV
replication in mouse embryo fibroblasts (MEFs) correlated
with induction of OAS (Nakamura et al., 1988). On the
other hand, overexpression of OAS had no effect on VSV
replication in CHO cells (Chebath et al., 1987).
More recent work has investigated the role of PKR and
RNase L in VSV replication using gene-deficient mice. IFN-
mediated inhibition of VSV replication in immortalized
PKR-deficient MEFs was unaffected, while inhibition was
reduced up to 100-fold in MEFs deficient in both PKR and
RNase L (Khabar et al., 2000). In contrast, another study
showed IFN-mediated inhibition of VSV was severely
compromised in PKR-deficient primary MEFs (Stojdl et
al., 2000). Similarly, in cells triply deficient in PKR, RNase
L and Mx1, IFN sensitivity was dramatically reduced, and
the primary cause of this reduction was the lack of PKR
(Zhou et al., 1999).
Other mechanisms for the inhibition of VSV replica-
tion by IFN have been reported. A soluble form of the
low density lipoprotein receptor, which was induced by
IFN-treatment and could be exogenously added to cells,
was shown to inhibit VSV infection. Its inhibitory
function occurred at late stages of infection (Fischer et
al., 1993). Most recently, a cellular, IFN-induced RNase,
ISG20, was shown to inhibit VSV replication when
overexpressed in cells, and expression of mutant forms
of this protein resulted in diminished antiviral effect of
IFN, indicating a novel role in IFN inhibition of VSV
(Espert et al., 2003).
Viral assembly has been shown to be a target of IFN
antiviral actions, as VSV particles with low infectivity were
secreted from mouse Ly(6) and L cells after IFN-treatment
(Maheshwari and Friedman, 1980; Maheshwari et al.,
1980a, 1980b). The low infectivity (bbaldQ) particles had
reduced glycoprotein G on the surface compared to wild
type virus, and it was observed that most intracellular G was
trapped in the trans-Golgi network, while G was mostly at
the plasma cell membrane in untreated cells (Singh et al.,
1988). Such studies indicated a novel IFN-induced antiviral
pathway that involved only modest RNA or protein
synthesis inhibition.
Our work suggests yet another novel IFN-induced
antiviral pathway in neuronal cells. While viral mRNA,
protein, and viral genomic RNA accumulation are reduced,
viral assembly and release are also compromised in
neurons. This inhibition is distinct from the release of
low infectivity bbaldQ particles from IFN-treated Ly(6) and
mouse L cells (Maheshwari and Friedman, 1980; Mahesh-
wari et al., 1980a, 1980b) in that the number of particles
released was severely decreased and appeared to contain a
normal amount of G protein. Further work needs to be
done to elucidate the mechanism of the defect in VSVmorphogenesis associated with type I IFN treatment of
neurons.
The reasons why VSV causes neurologic disease after
i.n. infection of immunocompetent mice but does not
replicate well peripherally (after introduction by any other
route) are not known. The ability of VSV to replicate well in
the CNS may potentially result from (a) insensitivity of
neurons to type I IFN inhibition of VSV, (b) lack of
induction of type I IFN production or release by VSV in the
CNS, or (c) adept evasion of IFN-induced antiviral path-
ways in the CNS compared to in the periphery. In this study,
it was shown that neuroblastoma cells and primary neurons
treated with type I IFN were highly resistant to VSV
infection, thus potentially excluding hypothesis (a). Addi-
tional studies indicated that type I IFN is not produced by
neurons in vitro or in vivo in the CNS following intranasal
infection, until after the infiltration of T cells (approximately
7 days pi) (Trottier, et al. in preparation); thus hypothesis b
has been implicated. Finally, VSV infection of many cell
types is characterized by elimination of host cell protein and
IFN synthesis by blockade of the nuclear pore by the VSV
M protein (Ahmed, et al, 2003; Enninga et al., 2002;
Glodowski et al., 2002).
The results indicate that neurons are responsive to type I
IFN and that type I IFN strongly inhibits VSV replication in
neurons. Despite this, VSV replicates to high levels in the
CNS of intranasally infected mice. Because of the high
sensitivity of neurons to type I IFN, the results are consistent
with a lack of IFN production in the CNS, which we have
observed (Trottier et al., in preparation). Indeed, mice
infected i.n. with VSV and subsequently treated with type
I IFN show improved survival and reduced viral replication
in the CNS (DeClercq and DeSomer, 1971; Gresser et al.,
1975; Tovey and Maury, 1999), supporting the idea that
neurons are responsive to type I IFN but insufficient IFN is
available.
We have shown that neurons are exquisitely sensitive to
the antiviral activity of Type I IFN, suppressing release of
infectious VSV by N3 log10. Our data indicate that VSV
infection is modestly suppressed for viral mRNA, protein,
and vRNA synthesis, which is consistent with the greatest
compromise to viral replication at assembly at release. The
VSV released appears to have the normal molar ratio of viral
proteins when compared to virus produced by untreated
cells. Work is in progress to elucidate the cellular blockade
in assembly and release of VSV.Materials and methods
Cells, viruses, and animals
Mouse neuroblastoma (NB41A3) cells were purchased
from ATCC and maintained in F12K medium with 15%
horse serum, 2.5% fetal bovine serum, 1% penicillin/
streptomycin. Chinese hamster ovary (CHO) and Madin–
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Huang and were maintained in Cellgro Free media with
10% fetal bovine serum, 1 mM l-glutamine and 1%
penicillin/streptomycin. BALB/c and C57BL/6 mice were
obtained from Taconic Laboratories. All mice were main-
tained in specific pathogen-free facilities at New York
University in accordance with UAWC guidelines. VSV
(Indiana strain, San Juan serotype) and Newcastle disease
virus (strain B1), (NDV) the gift of Peter Palese, Mt Sinai
School of Medicine, were used for virus infections.
In vitro IFN treatment
NB41A3 cells were treated with IFN-h (R and D
Systems) or IFN-a (RDI) prior to infection as described in
the figure legends. Cells were infected by incubating VSVor
NDV with cells for 30 min or 1 h, respectively, at 37 8C in
F12K medium. Virus was aspirated from cells and fresh
media were added. Virus infection continued for indicated
times before cell supernatants were harvested.
Cell lysates for Western blots were prepared by washing
cells one time with HBSS followed by addition of lysis
buffer (20 mM Tris pH 7.4, 0.5 M NaCl, 0.5% NP-40, 5
mM EDTA, 2 mM Na3VO4, 2 mM PMSF, 1 Ag/ml
pepstatin, 0.5 Ag/ml leupeptin, 2 Ag/ml aprotinin) and
incubation for 30 min on ice. Protein concentration was
estimated using Bio-Rad Dc Protein Assay kit.
Total RNA was prepared using Trizol (Invitrogen)
following manufacturer’s recommendations. To eliminate
DNA contamination, total RNA was treated with DNase I
(DNA-free, Ambion) and precipitated with LiCl. RNA was
quantified by UV absorption before use.
Preparation of primary olfactory neurons
Primary culture of murine olfactory neurons was
performed as described (Chesler et al., 2003). Briefly,
olfactory bulbs from C57BL/6 or BALB/c mice were
dissected from P0 (b24 h old) mice, dissociated by
enzymatic digestion (porcine trypsin 2.5%, Life Techno-
logies) and manually triturated using flame-polished
Pasteur pipets. Cultures were plated in wells of poly-l-
lysine-coated 24-well plates in DMEM with 10% FBS,
10 mM KCl, 10 AM l-glutamine, 1% penicillin/strepto-
mycin for 30 min at 37 8C/5% CO2, after which AraC was
added to a final concentration of 10 AM. Cells were
allowed to incubate for 36 h at 37 8C/5% CO2, after which
media were replaced by Neurobasal Media (Life Technol-
ogies) with 1% N2 supplement, 0.5 mM l-glutamine,
25AM l-glutamic acid, 10 mM KCl, and 1% penicillin/
streptomycin. Cultures were comprised of N90% neurons
determined by staining for MAP-2B. The remaining
fraction was comprised of cells such as activated astro-
cytes, as determined by glial fibrillary acidic protein
(GFAP) staining. All experiments were performed on day
4 of culture.Plaque assays
Confluent monolayers of CHO cells in 24-well plates
were infected with 0.1 ml serially diluted samples for
30 min at 37 8C, after which 1 ml of Joklik’s growth
medium/0.9% agar was added to each well. Plates were
incubated 18–22 h at 37 8C, fixed with 10% buffered
formalin and stained with 0.5% methylene blue, after which
plaques were counted.
Immunofluorescence studies
NB41A3.NS1 cells harboring stably transfected plas-
mid pcDNA3-PR8NS1(SAM) were prepared previously
(Chesler et al., 2003). This plasmid expresses the
influenza A NS1 protein under the control of a CMV
promoter, and is selected by G418 (500 Ag/ml). NB41A3
or NB41A3.NS1 cells were grown on 4-well chamber
slides and infected with either VSV or NDV at a
multiplicity of infection (moi) = 10. At various times pi,
cells were washed and treated with 200 Al 10% buffered
formalin in PBS for 5 min at 4 8C, washed again, and
then permeabilized with 1% Triton X-100 in PBS at 4 8C
for 10 min. After washing, slides were incubated over-
night at 4 8C with 5% goat serum, 1% BSA in PBS, then
incubated for 2 h at 20 8F (room temperature, rt) with
rabbit anti-IRF-3 (Zymed) at a concentration of 0.75 Ag/
ml in 1% BSA-PBS. Cells were washed with PBS and
incubated with goat anti-rabbit Alexafluor 488-conjugated
secondary antibody (Molecular Probes) for 1 h at rt.
Slides were washed before mounting in Permount
containing Pro-Long antifade reagent (Molecular Probes)
and DAPI (0.5 mg/ml).
Western blots
Cell lysates were electrophoresed on 10% polyacryla-
mide/SDS gels and transferred to nitrocellulose membranes
by electroblotting for 1 h. Membranes were blocked with
5% non-fat milk in TTBS (25 mM Tris pH 7.4, 137 mM
NaCl, 2.7 mM KCl, 0.2% Tween-20) for 30 min at room
temperature, incubated with primary antibody in 5% milk in
TTBS for 2 h at rt, washed with TTBS, incubated with
secondary antibody in 5% milk in TTBS for 1.5 h at rt and
washed again. Signal was detected using Pierce Supersignal
reagent and autoradiography. Primary antibodies used were
sheep anti-VSV (1:100,000), mouse anti-eIF-2a (1:1000;
Biosource), rabbit anti-phosphorylated eIF-2a (1:1000;
Biosource), mouse anti-tubulin III (1:20,000) and rabbit
anti-GAPDH (1:10,000; AbCam). Secondary antibodies
were HRP-labeled donkey anti-sheep IgG (1:10,000),
HRP-labeled goat anti-rabbit IgG (1:4000)(Jackson Immu-
noresearch) and peroxidase-labeled donkey anti-mouse IgG
(1:2000; Vector labs).
Levels of protein were quantified using UN-SCAN-IT
software (Silk Scientific), and normalized to housekeeping
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eIF-2a and phosphorylated eIF-2a).
Northern blots
NB41A3 cells were pre-treated with IFN-h (100 units/
ml) or mock treated with media for 18 h at 37 8C/5% CO2.
Cells were infected with VSV at moi = 0.1 or 1 and
infection was allowed to proceed for various times. Total
RNA was isolated from cells using Trizol (Invitrogen). Ten
Ag of total RNA from each sample was electrophoresed in
denaturing 1% agarose gels, and RNA was transferred to
Zetaprobe GT membranes (BioRad) overnight by passive
diffusion. RNA was fixed to membranes by UV irradiation.
For detection of full-length genomic viral RNA, RNA
isolated from purified VSV particles was used as a control.
To confirm identity of full-length viral RNA, Northern blots
were performed using either the VSV M or VSV L probes
alone (data not shown).
Probes for Northern blotting were generated as
described (Komatsu et al., 1999) using the PCR DIG Probe
Synthesis Kit (Roche). For VSV genes, individual plasmids
encoding VSV M, L, N, P, and G were used to generate
DIG-labeled probes (Lawson et al., 1995). For GAPDH,
NB41A3 total RNA was reverse transcribed and resulting
cDNA was used as template for generation of DIG-labeled
probe.
Membranes were pre-hybridized with DIG Easy Hyb
(Roche) at 42 8C for 30 min, after which membranes were
incubated with fresh DIG Easy Hyb containing DIG-labeled
probes (2Al probe per ml hybridization buffer) overnight at
42 8C. Membranes were then washed once in 1 SSC, 0.1%
SDS at room temperature and then three times in 0.2 SSC,
0.1% SDS for 20 min each at 42 8C.
After hybridization, DIG-labeled probes were detected
using the DIG Wash and Block Buffer set, anti-digoxigenin-
AP Fab fragments and CSPD chemiluminescent substrate
(Roche), according to the manufacturer’s suggestions.
Hybridization was detected by exposure of membranes to
film and quantified by UN-SCAN-IT software.
Analysis of release of VSV particles from IFN-treated cells
NB41A3 cells or primary olfactory neurons were pre-
treated with IFN-h (100 units/ml) or mock-treated with
media for 18 h and then infected with VSV at moi = 0.1. At
7 h pi (unless otherwise noted), supernatants were collected
and subjected to ultracentrifugation through 15% sucrose in
PBS in an SW28 rotor at 17,000 rpm at 4 8C. Supernatants
from NB41A3 cultures were from 2 wells of a 6-well plate,
corresponding to approximately 1–2  106 cells. Super-
natants from primary neurons were from 1 well of a 24-well
plate, corresponding to approximately 1  105 cells. Pellets
were resuspended in SDS-PAGE loading buffer and boiled
for 5 min. Samples were subjected to Western blotting to
detect VSV proteins.Acknowledgments
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